417 reports of this reaction
2.3% of all THIOTEPA reports
#9 most reported adverse reaction
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN is the #9 most commonly reported adverse reaction for THIOTEPA, manufactured by Amneal Pharmaceuticals LLC. There are 417 FDA adverse event reports linking THIOTEPA to ACUTE GRAFT VERSUS HOST DISEASE IN SKIN. This represents approximately 2.3% of all 18,516 adverse event reports for this drug.
Patients taking THIOTEPA who experience acute graft versus host disease in skin should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN is a less commonly reported adverse event for THIOTEPA, but still significant enough to appear in the safety profile.
In addition to acute graft versus host disease in skin, the following adverse reactions have been reported for THIOTEPA:
The following drugs have also been linked to acute graft versus host disease in skin in FDA adverse event reports:
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN has been reported as an adverse event in 417 FDA reports for THIOTEPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN accounts for approximately 2.3% of all adverse event reports for THIOTEPA, making it a notable side effect.
If you experience acute graft versus host disease in skin while taking THIOTEPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.